Now the vaccine is in the third stage of clinical trials.
ChAdOx1 vaccine which was developed against the coronavirus SARS-CoV-2, can go on sale in January 2021.
As reported by Naked Science, in an interview with the newspaper Libero said the Director of the research center of Pomezia Irbm Piero Di Lorenzo.
The vaccine was developed by scientists from Generalscope Institute at the University of Oxford, tests were conducted the test in collaboration with the British pharmaceutical Corporation AstraZeneca and the Italian centre of Irbm Pomezia.
It is noted that ChAdOx1 based on the chimpanzee adenovirus containing a full-sized structural surface glycoprotein (S protein) of SARS-CoV-2 with the leader sequence of the plasminogen activator. She is now in the third stage of clinical tests involving about 10 thousand people.
The end of the studies scheduled for September, it will also attract 30 thousand people in the United States, two thousand South Africans and five thousand Brazilians. As noted by Di Lorenzo, first organize the vaccination of people who belong to groups most at risk of Contracting coronavirus.
In accordance with the previous agreements, ChAdOx1 will first appear in Italy and great Britain, then in the Netherlands, France and Germany. The United Kingdom, according to BBC, has already ordered 100 million doses of vaccine. The head of Irbm Pomezia sure that vaccination to take place rapidly, so that within 12 months, “the planet will be protected.” The commercial price of the drug will be about two to three euros.
Read the latest news of Ukraine and peace in the channel, the UNIAN in a Telegram.